JP6501946B2 - 抗腫瘍化合物 - Google Patents

抗腫瘍化合物 Download PDF

Info

Publication number
JP6501946B2
JP6501946B2 JP2018086736A JP2018086736A JP6501946B2 JP 6501946 B2 JP6501946 B2 JP 6501946B2 JP 2018086736 A JP2018086736 A JP 2018086736A JP 2018086736 A JP2018086736 A JP 2018086736A JP 6501946 B2 JP6501946 B2 JP 6501946B2
Authority
JP
Japan
Prior art keywords
cancer
compound
small cell
lung cancer
cell lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018086736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018188431A5 (enExample
JP2018188431A (ja
Inventor
マリア・デル・カルメン・ケヴァス・マルシャンテ
アンドレス・フランセスク・ソリョーソ
バレンティン・マルティネス・バラサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma Mrs sA
Original Assignee
Pharma Mrs sA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mrs sA filed Critical Pharma Mrs sA
Publication of JP2018188431A publication Critical patent/JP2018188431A/ja
Publication of JP2018188431A5 publication Critical patent/JP2018188431A5/ja
Application granted granted Critical
Publication of JP6501946B2 publication Critical patent/JP6501946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
JP2018086736A 2017-04-27 2018-04-27 抗腫瘍化合物 Active JP6501946B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17382228.9 2017-04-27
EP17382228 2017-04-27
EP17382497.0 2017-07-26
EP17382497 2017-07-26

Publications (3)

Publication Number Publication Date
JP2018188431A JP2018188431A (ja) 2018-11-29
JP2018188431A5 JP2018188431A5 (enExample) 2019-01-17
JP6501946B2 true JP6501946B2 (ja) 2019-04-17

Family

ID=62063080

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018086736A Active JP6501946B2 (ja) 2017-04-27 2018-04-27 抗腫瘍化合物
JP2019558467A Active JP7186723B2 (ja) 2017-04-27 2018-04-27 抗腫瘍化合物
JP2018086737A Active JP6501947B2 (ja) 2017-04-27 2018-04-27 抗腫瘍化合物
JP2022107785A Active JP7422812B2 (ja) 2017-04-27 2022-07-04 抗腫瘍化合物
JP2023008821A Active JP7490835B2 (ja) 2017-04-27 2023-01-24 抗腫瘍化合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019558467A Active JP7186723B2 (ja) 2017-04-27 2018-04-27 抗腫瘍化合物
JP2018086737A Active JP6501947B2 (ja) 2017-04-27 2018-04-27 抗腫瘍化合物
JP2022107785A Active JP7422812B2 (ja) 2017-04-27 2022-07-04 抗腫瘍化合物
JP2023008821A Active JP7490835B2 (ja) 2017-04-27 2023-01-24 抗腫瘍化合物

Country Status (39)

Country Link
US (5) US10538535B2 (enExample)
EP (5) EP3615544B9 (enExample)
JP (5) JP6501946B2 (enExample)
KR (3) KR102510975B1 (enExample)
CN (4) CN114751920B (enExample)
AU (4) AU2018260314C1 (enExample)
BR (1) BR112019022282A2 (enExample)
CA (1) CA3061518A1 (enExample)
CL (1) CL2019003057A1 (enExample)
CO (1) CO2019011967A2 (enExample)
CY (3) CY1121885T1 (enExample)
DK (5) DK3395820T3 (enExample)
EC (1) ECSP19083967A (enExample)
ES (5) ES2741901T3 (enExample)
FI (3) FI3615544T3 (enExample)
HK (2) HK1255938B (enExample)
HR (5) HRP20230433T1 (enExample)
HU (5) HUE062032T2 (enExample)
IL (3) IL270153B2 (enExample)
JO (1) JOP20190254A1 (enExample)
LT (5) LT3395821T (enExample)
MA (2) MA44021B1 (enExample)
MD (5) MD3615544T2 (enExample)
ME (2) ME03466B (enExample)
MX (3) MX392601B (enExample)
MY (1) MY198004A (enExample)
PH (1) PH12019550224A1 (enExample)
PL (5) PL4101855T3 (enExample)
PT (2) PT3395821T (enExample)
RS (5) RS64200B1 (enExample)
SA (1) SA523440283B1 (enExample)
SG (2) SG11201909841RA (enExample)
SI (5) SI4047002T1 (enExample)
SM (5) SMT202300169T1 (enExample)
TN (2) TN2019000210A1 (enExample)
TW (3) TWI875118B (enExample)
UY (1) UY37706A (enExample)
WO (1) WO2018197663A1 (enExample)
ZA (1) ZA201907119B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020517709A (ja) * 2017-04-27 2020-06-18 ファルマ、マール、ソシエダード、アノニマＰｈａｒｍａ Ｍａｒ，Ｓ．Ａ． 抗腫瘍化合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
PH12022551216A1 (en) * 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations
CA3175426A1 (en) * 2020-04-21 2021-10-28 Alfonso Latorre Lozano Drug antibody conjugates
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
CA3218171A1 (en) 2021-05-19 2022-11-24 Carmen KAHATT Dosage regimens for ecubectedin
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
EP4563149A1 (en) 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
TW202532075A (zh) * 2024-02-08 2025-08-16 大陸商映恩生物製藥（蘇州）有限公司 海鞘素類化合物及其應用
WO2025228595A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
WO2025228597A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of compound ia and a topoisomerase i inhibitor in the treatment of cancer
WO2025228596A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer
WO2025228594A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab
WO2025233522A1 (en) 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
EP0048149B1 (en) 1980-09-12 1983-11-30 University of Illinois Foundation Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
AU585936B2 (en) 1984-12-28 1989-06-29 Conpharm A.B. Pharmaceutically active podophyllotoxins
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
DE3684868D1 (de) 1985-09-20 1992-05-21 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
EP0309477B1 (en) 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
ES2054011T3 (es) 1988-09-05 1994-08-01 Sankyo Co Un proceso para la preparacion de un compuesto, "leualacina".
WO1990005731A1 (en) 1988-11-24 1990-05-31 University Of Queensland Cytotoxic macromolecules
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (en) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
WO1994004541A2 (en) 1992-08-12 1994-03-03 The Upjohn Company Protein kinase inhibitors and related compounds combined with taxol
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
AU731757B2 (en) 1996-10-24 2001-04-05 Board Of Trustees Of The University Of Illinois, The Semi-synthetic studies toward didemnin analogues
EP0956033B1 (en) 1996-10-24 2003-07-23 The Board Of Trustees Of The University Of Illinois Total synthesis of the amino hip analogue of didemnin a
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
EP0981352B8 (en) 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CZ301083B6 (cs) 1998-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
DK1076486T3 (da) 1998-05-05 2006-01-09 Pharma Mar Sa Dyrkning af sessile marine dyr
CN1195514C (zh) * 1998-05-11 2005-04-06 法马马有限公司 海鞘素 743的代谢物
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
WO2001035974A2 (en) 1999-11-15 2001-05-25 Pharma Mar S.A. Aplidine treatment of cancers
EP1254140A4 (en) 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USES AND SYNTHESIS
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
ATE316524T1 (de) 2000-02-16 2006-02-15 Pharma Mar Sa Oxy- und aminosubstituierte tetrahydrofurylderivate mit antitumoraktivität
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
RU2323000C2 (ru) 2000-04-07 2008-04-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Аналоги тамандарина и дидемнина и способы их получения и применения
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
DE60111845T2 (de) 2000-04-12 2006-04-27 Pharma Mar, S.A., Tres Cantos Ecteinaschidin derivate mit antikrebs wirkung
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
CA2410409A1 (en) 2000-06-06 2001-12-13 Pharma Mar, S.A. Antitumoral compounds
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CN1324028C (zh) 2000-07-11 2007-07-04 法马马有限公司 作为抗癌剂的变曲霉素衍生物
AU2001273471B8 (en) 2000-07-13 2006-08-31 Recor Medical, Inc. Thermal treatment methods and apparatus with focused energy application
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
HUP0302293A3 (en) 2000-10-12 2006-04-28 Pharma Mar Sa Treatment of cancers by aplidine in conjunction with a myoprotector
NZ525196A (en) 2000-10-12 2004-09-24 Pharma Mar S Treatment of cancers by aplidine in conjunction with a myoprotector
ATE314084T1 (de) 2000-10-31 2006-01-15 Pharma Mar Sa Kahalalid f formulierung
US20040108086A1 (en) 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
EP1353659A1 (de) 2001-01-24 2003-10-22 Mestex AG Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
KR20050038578A (ko) 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
DE60229414D1 (de) 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
CA2462639A1 (en) 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
CN101077885A (zh) 2002-10-18 2007-11-28 马尔药品公司 新型抗肿瘤化合物
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
EP2289559B1 (en) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
DK1603584T3 (da) 2003-03-12 2009-01-05 Dana Farber Cancer Inst Inc Aplidine til behandling af multipelt myelom
KR20060002778A (ko) 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
EP1613338A4 (en) 2003-03-21 2009-06-24 Madeleine M Joullie TAMANDARIN ANALOGUES, FRAGMENTS THEREOF AND METHODS OF MAKING AND USING THE SAME
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
MXPA06000975A (es) 2003-07-25 2006-04-11 Novartis Ag Lactams sustituidos y su uso como agentes anti-cancer.
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
CA2540868A1 (en) 2003-10-09 2005-04-21 Abbott Laboratories Pyrrolidinyl urea derivatives as angiogenesis inhibitors
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
US20080293725A1 (en) 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
JP2008514688A (ja) 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
HRP20090345T1 (en) 2004-10-26 2009-08-31 Pharma Mar S.A. Pegylated liposomal doxorubicin in combination with ecteinescidin 743
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
KR20080007640A (ko) 2005-05-03 2008-01-22 파르마 마르 에스.에이., 소시에다드 유니퍼스널 항암성 테트라하이드로-피리미딘
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
EP1925668A2 (en) 2005-08-02 2008-05-28 Pharma Mar, S.A. Genes involved in the biosynthesis of thiocoraline and heterologous production of same
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
WO2007062413A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
DK2029155T3 (en) 2006-02-28 2016-08-01 Pharma Mar Sa IMPROVED treatment of multiple myeloma
WO2007134203A2 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
WO2007144423A1 (en) 2006-06-16 2007-12-21 Pharma Mar, S.A. Antitumoral dihydropyran-2-one compounds
CA2703024A1 (en) 2007-10-19 2009-04-23 Giuseppe Longo Sorbello Improved antitumoral treatments
AU2008312400A1 (en) 2007-10-19 2009-04-23 Albert Einstein College Of Medicine Of Yeshiva University Improved antitumoral treatments
US20100267732A1 (en) 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
CA2708080C (en) 2007-12-14 2016-06-14 Pharma Mar, S.A. Antitumoral compounds
EP2597091B1 (en) 2007-12-20 2016-04-20 Pharma Mar, S.A. Antitumoral Compounds
EP2252315A1 (en) 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
MX2010009697A (es) 2008-03-07 2010-09-30 Pharm Mar S A Tratamientos anticancerigenos mejorados.
EP2262522A1 (en) 2008-03-07 2010-12-22 Pharma Mar, S.A. Improved antitumoral treatments
CN102099025A (zh) 2008-05-16 2011-06-15 马尔药品公司 Pm00104与另一抗肿瘤剂的联合疗法
WO2009138509A1 (en) 2008-05-16 2009-11-19 Pharma Mar, S.A. Multiple myeloma treatments
KR101331341B1 (ko) 2008-05-23 2013-11-19 와이어쓰 엘엘씨 Ｐｉ３ 키나제 및 ｍｔｏｒ 억제제로서의 트리아진 화합물
KR20110043653A (ko) 2008-07-03 2011-04-27 파르마 마르 에스.에이. 항종양 마크롤라이드
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
EP2318428A1 (en) 2008-07-17 2011-05-11 Pharma Mar S.A. Anticancer compounds
JP2012512839A (ja) 2008-12-19 2012-06-07 ファルマ、マール、ソシエダード、アノニマ 抗腫瘍性化合物
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
CN102947322B (zh) 2010-04-27 2016-09-07 法马马有限公司 在7（8）位不饱和的抗癌甾体内酯
CA2800097C (en) * 2010-05-25 2019-01-08 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds and intermediates
KR102452022B1 (ko) 2010-11-12 2022-10-06 파르마 마르 에스.에이. 항종양 알칼로이드를 이용한 병용요법
DE102012211024B4 (de) 2012-06-27 2024-10-24 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
MX2019000536A (es) 2016-07-14 2019-04-01 Pfizer Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020517709A (ja) * 2017-04-27 2020-06-18 ファルマ、マール、ソシエダード、アノニマＰｈａｒｍａ Ｍａｒ，Ｓ．Ａ． 抗腫瘍化合物
JP7186723B2 (ja) 2017-04-27 2022-12-09 ファルマ、マール、ソシエダード、アノニマ 抗腫瘍化合物

Also Published As

Publication number Publication date
SA523440283B1 (ar) 2025-04-26
AU2022200249C1 (en) 2022-06-23
CN114751920A (zh) 2022-07-15
TWI807411B (zh) 2023-07-01
MX2021016058A (es) 2022-02-03
HUE046109T2 (hu) 2020-02-28
PL3615544T3 (pl) 2023-07-17
ES2741901T3 (es) 2020-02-12
LT3395821T (lt) 2019-08-12
EP3615544B1 (en) 2023-03-22
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
LT4101855T (lt) 2023-08-25
HK1255938B (en) 2020-04-29
DK4047002T3 (da) 2023-05-01
AU2018260314B2 (en) 2021-12-09
HRP20230455T1 (hr) 2023-07-21
DK4101855T3 (da) 2023-11-06
AU2022200250C1 (en) 2022-06-23
UY37706A (es) 2018-11-30
ES2944344T3 (es) 2023-06-20
DK3395820T3 (da) 2019-08-12
TW202344509A (zh) 2023-11-16
SMT202300160T1 (it) 2023-07-20
SI4047002T1 (sl) 2023-07-31
US20240166666A1 (en) 2024-05-23
MA44021B1 (fr) 2019-08-30
US20220242883A1 (en) 2022-08-04
IL270153A (enExample) 2019-12-31
JP7490835B2 (ja) 2024-05-27
US10538535B2 (en) 2020-01-21
US11713325B2 (en) 2023-08-01
US20210246146A1 (en) 2021-08-12
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
EP3395820A1 (en) 2018-10-31
TW202202509A (zh) 2022-01-16
WO2018197663A1 (en) 2018-11-01
CN114751920B (zh) 2024-06-07
EP4101855B9 (en) 2024-01-03
HRP20231233T1 (hr) 2024-01-19
JP2018188431A (ja) 2018-11-29
CN117865987A (zh) 2024-04-12
SI3615544T1 (sl) 2023-07-31
ZA201907119B (en) 2021-07-28
AU2022201657A1 (en) 2022-03-31
PL4047002T3 (pl) 2023-07-24
CY1126061T1 (el) 2023-11-15
FI4047002T3 (fi) 2023-05-22
IL295044B1 (en) 2023-07-01
ME03466B (me) 2020-01-20
SG11201909841RA (en) 2019-11-28
AU2018260314C1 (en) 2022-04-21
JP7422812B2 (ja) 2024-01-26
LT3615544T (lt) 2023-05-10
CY1121885T1 (el) 2020-10-14
HRP20230433T1 (hr) 2023-07-07
CL2019003057A1 (es) 2020-02-21
NZ797532A (en) 2025-06-27
CO2019011967A2 (es) 2020-02-18
CY1121884T1 (el) 2020-10-14
IL289963B1 (en) 2023-06-01
AU2022200250B1 (en) 2022-02-10
JP2020517709A (ja) 2020-06-18
NZ797531A (en) 2025-06-27
KR20220109495A (ko) 2022-08-04
JP2018188432A (ja) 2018-11-29
KR102510975B1 (ko) 2023-03-16
SMT202300169T1 (it) 2023-07-20
JP7186723B2 (ja) 2022-12-09
PT3395820T (pt) 2019-08-07
HUE062032T2 (hu) 2023-09-28
EP4047002B1 (en) 2023-03-08
IL295044B2 (en) 2023-11-01
TN2019000210A1 (en) 2021-01-07
RS59174B1 (sr) 2019-10-31
EP4101855A1 (en) 2022-12-14
KR102492283B1 (ko) 2023-01-27
MX392601B (es) 2025-03-24
TN2019000211A1 (en) 2021-01-07
CN110621678A (zh) 2019-12-27
SMT202300343T1 (it) 2023-11-13
KR102491180B1 (ko) 2023-01-20
DK3395821T3 (da) 2019-08-19
SMT201900447T1 (it) 2019-09-09
PH12019550224A1 (en) 2020-10-12
LT3395820T (lt) 2019-08-12
MX2021016054A (es) 2022-06-01
IL270153B2 (en) 2023-10-01
ES2740073T3 (es) 2020-02-05
IL270153B1 (en) 2023-06-01
KR20210126791A (ko) 2021-10-20
JP2022130682A (ja) 2022-09-06
SG10201913300YA (en) 2020-03-30
FI3615544T3 (fi) 2023-05-23
JP6501947B2 (ja) 2019-04-17
PT3395821T (pt) 2019-08-27
RS59173B1 (sr) 2019-10-31
NZ758490A (en) 2025-06-27
TWI742273B (zh) 2021-10-11
MD3395820T2 (ro) 2019-10-31
HUE063736T2 (hu) 2024-01-28
MY198004A (en) 2023-07-25
ECSP19083967A (es) 2019-12-27
KR20200012846A (ko) 2020-02-05
CN114736219A (zh) 2022-07-12
SMT201900448T1 (it) 2019-09-09
US20210070775A1 (en) 2021-03-11
EP3395821A1 (en) 2018-10-31
AU2022200249B1 (en) 2022-02-10
HRP20191443T1 (hr) 2019-11-15
AU2018260314A1 (en) 2019-10-31
PL3395821T3 (pl) 2019-10-31
MA44020A (fr) 2018-10-31
TW201906850A (zh) 2019-02-16
US12384800B2 (en) 2025-08-12
DK3615544T3 (da) 2023-05-30
SI3395820T1 (sl) 2019-09-30
MA44021A (fr) 2019-05-15
US20180312529A1 (en) 2018-11-01
IL295044A (en) 2022-09-01
ME03467B (me) 2020-01-20
ES2944579T3 (es) 2023-06-22
MX392829B (es) 2025-03-24
JP2023052597A (ja) 2023-04-11
EP3395821B1 (en) 2019-05-15
HRP20191442T1 (hr) 2019-11-15
EP3615544A1 (en) 2020-03-04
TWI875118B (zh) 2025-03-01
EP3615544B9 (en) 2024-01-03
MD3615544T2 (ro) 2023-08-31
BR112019022282A2 (pt) 2020-05-19
CN114736219B (zh) 2024-06-07
HK1255941B (en) 2020-04-29
MX2019012812A (es) 2020-01-14
CN110621678B (zh) 2024-09-20
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
EP4101855B1 (en) 2023-08-02
EP3395820B1 (en) 2019-05-15
IL289963A (en) 2022-03-01
RS64200B1 (sr) 2023-06-30
HUE045641T2 (hu) 2020-01-28
EP4047002A1 (en) 2022-08-24
JOP20190254A1 (ar) 2019-10-27
HUE062157T2 (hu) 2023-10-28
MD4047002T2 (ro) 2023-08-31
RS64686B1 (sr) 2023-11-30
FI4101855T3 (fi) 2023-09-22
IL289963B2 (en) 2023-10-01
ES2960063T3 (es) 2024-02-29
CA3061518A1 (en) 2018-11-01
SI3395821T1 (sl) 2019-09-30
SI4101855T1 (sl) 2024-03-29
RS64174B1 (sr) 2023-05-31
LT4047002T (lt) 2023-05-10
US11332480B2 (en) 2022-05-17

Similar Documents

Publication Publication Date Title
JP6501946B2 (ja) 抗腫瘍化合物
HK1255941A1 (en) Antitumoral compounds
HK1255938A1 (en) Antitumoral compounds
EA023646B1 (ru) Замещённые соли 2,3-дигидроимидазо[1,2-c]хиназолина
US7951780B2 (en) Antitumor agent
AU2002237884B2 (en) Anticancer treatment using triptolide prodrugs
KR20190077476A (ko) 상글리페린 거대고리 유사체의 항암 화합물로서의 용도
JPH06192109A (ja) 抗腫瘍効果増強剤
JP2025138792A (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
JP4162994B2 (ja) 諸疾患状態の処置のための薬物に使用する化合物とその製造方法
US20100003346A1 (en) Combination methods of treating cancer
WO2022235889A1 (en) Hsp90-binding conjugates and formulations thereof
JP2013525290A5 (enExample)
US8022047B2 (en) Combination anticancer agents
CN102625805A (zh) 治疗癌症的化合物和组分
ES2683424T3 (es) Formulaciones de romidepsina y usos de estas
WO2017142269A1 (ko) 신규한 인돌 유도체 및 이를 포함하는 항암 조성물
US20170071959A1 (en) Novel derivatives of oxazaphosphorines and therapeutic uses thereof
JP6803589B2 (ja) 抗腫瘍剤
CN108498518A (zh) 七元环小檗碱类似物及其药物组合物在制备治疗血液肿瘤的药物中的应用
EP4534543A1 (en) Camptothecin prodrug and pharmaceutical composition thereof
AU2003296872A1 (en) Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases
US20070286906A1 (en) Dihydrobenzoquinone compounds
CN110573165B (zh) 3’-脱氨基-3’-(2’’-吡咯啉-1’’-基)-5-亚氨基-13-脱氧蒽环及制备方法
WO2024247648A1 (ja) 腫瘍の治療剤及び複合体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181109

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20181109

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20181121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190319

R150 Certificate of patent or registration of utility model

Ref document number: 6501946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250